Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Rejects Bevacizumab Drug For Use In Wet AMD

European Commission Approves COVID-19 Products Ronapreve & Regkirona

Executive Summary

Nearly a year and a half after it was filed for approval, the EU regulator has rejected a mystery injectable product containing the monoclonal antibody bevacizumab for ophthalmic use.

You may also be interested in...



Biosimilar Insulins Satisfy EMA’s CHMP

The EMA’s CHMP has issued positive opinions for two insulin biosimilars: Sanofi’s insulin aspart rival to NovoMix and Baxter’s insulin human (rDNA) version of Actrapid. At the same time, the CHMP has confirmed its recommendation to refuse marketing authorization for the Ipique ophthalmic version of bevacizumab.

Accord’s Teriparatide And Fresenius Kabi’s Pegfilgrastim Satisfy CHMP

Positive CHMP opinions recommending European marketing authorizations have been granted for Accord’s teriparatide and Fresenius Kabi’s pegfilgrastim biosimilars, while the sponsor for an ophthalmic version of bevacizumab has asked the EMA to take a second look at the rejection of its application. Three Accord generics were also endorsed by the CHMP at its January meeting.

Ophthalmic Bevacizumab Sponsor Not Giving Up On EMA Rejection

The European Medicines Agency has been asked to re-examine its rejection of the EU marketing application for Ipique, which, if approved, could become the first drug containing bevacizumab to be authorized for use in neovascular (wet) macular degeneration.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel